Literature DB >> 34112117

Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana.

Kofi Boamah Mensah1,2, Adwoa Bemah Boamah Mensah3, Varsha Bangalee4, Neelaveni Padayachee5, Frasia Oosthuizen4.   

Abstract

INTRODUCTION: Access to childhood cancer medicines is a critical global health challenge. There is a lack of sufficient context-specific data in Ghana on access to essential medicines for treating childhood cancers. Here, we present an analysis of essential cancer medicine availability, pricing, and affordability using the pediatric oncology unit of a tertiary hospital as the reference point.
METHOD: Data on prices and availability of 20 strength-specific essential cancer medicines and eight non-cancer medicines were evaluated using the modified World Health Organization (WHO)/Health Action International method. Two pharmacies in the hospital and four private pharmacies around the hospital were surveyed. We assessed their median price ratio using the WHO international reference price guide. The number of days wages per the government daily wage salary was used to calculate the affordability of medicines.
RESULTS: The mean availability of essential cancer medicines and non-cancer medicines at the hospital pharmacies were 27 and 38% respectively, and 75 and 84% respectively for private pharmacies. The median price ratio of cancer medicines was 1.85, and non-cancer medicines was 3.75. The estimated cost of medicines for treating a 30 kg child with Acute lymphoblastic leukaemia was GHȻ 4928.04 (US$907.56) and GHȻ 4878.00 (US$902.62) for Retinoblastoma, requiring 417 and 413-days wages respectively for the lowest-paid unskilled worker in Ghana.
CONCLUSION: The mean availability of cancer medicines at the public and private pharmacies were less than the WHO target of 80%. The median price ratio for cancer and non-cancer medicines was less than 4, yet the cost of medicines appears unaffordable in the local setting. A review of policies and the establishment of price control could improve availability and reduce medicines prices for the low-income population.

Entities:  

Keywords:  Affordability; Availability; Childhood cancer; Ghana; Medicines; Price

Year:  2021        PMID: 34112117     DOI: 10.1186/s12885-021-08435-x

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  21 in total

Review 1.  Childhood cancer burden: a review of global estimates.

Authors:  Nickhill Bhakta; Lisa M Force; Claudia Allemani; Rifat Atun; Freddie Bray; Michel P Coleman; Eva Steliarova-Foucher; A Lindsay Frazier; Leslie L Robison; Carlos Rodriguez-Galindo; Christina Fitzmaurice
Journal:  Lancet Oncol       Date:  2019-01       Impact factor: 41.316

Review 2.  Economic evaluation of pediatric cancer treatment: a systematic literature review.

Authors:  Heidi V Russell; Janki Panchal; Helena Vonville; Luisa Franzini; J Michael Swint
Journal:  Pediatrics       Date:  2012-12-24       Impact factor: 7.124

3.  ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.

Authors:  N I Cherny; R Sullivan; J Torode; M Saar; A Eniu
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

4.  The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi.

Authors:  Nickhill Bhakta; Alexandra L C Martiniuk; Sumit Gupta; Scott C Howard
Journal:  Arch Dis Child       Date:  2012-11-30       Impact factor: 3.791

Review 5.  Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.

Authors:  Carlos Rodriguez-Galindo; Paola Friedrich; Patricia Alcasabas; Federico Antillon; Shripad Banavali; Luis Castillo; Trijn Israels; Sima Jeha; Mhammed Harif; Michael J Sullivan; Thuan Chong Quah; Catherine Patte; Ching-Hon Pui; Ronald Barr; Thomas Gross
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology.

Authors:  Abhishek Sharma; Lindsey Rorden; Margaret Ewen; Richard Laing
Journal:  J Pharm Policy Pract       Date:  2016-04-05

7.  Medicines for cancers in children: The WHO model for selection of essential medicines.

Authors:  Jane Robertson; Nicola Magrini; Ronald Barr; Gilles Forte; Clive Ondari
Journal:  Pediatr Blood Cancer       Date:  2015-04-30       Impact factor: 3.167

8.  International incidence of childhood cancer, 2001-10: a population-based registry study.

Authors:  Eva Steliarova-Foucher; Murielle Colombet; Lynn A G Ries; Florencia Moreno; Anastasia Dolya; Freddie Bray; Peter Hesseling; Hee Young Shin; Charles A Stiller
Journal:  Lancet Oncol       Date:  2017-04-11       Impact factor: 41.316

9.  Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology.

Authors:  Lombe Kasonde; David Tordrup; Aliya Naheed; Wu Zeng; Shyfuddin Ahmed; Zaheer-Ud-Din Babar
Journal:  BMC Health Serv Res       Date:  2019-06-13       Impact factor: 2.655

10.  Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India.

Authors:  Neha Faruqui; Alexandra Martiniuk; Abhishek Sharma; Chanchal Sharma; Bhumika Rathore; Ramandeep Singh Arora; Rohina Joshi
Journal:  BMJ Glob Health       Date:  2019-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.